98%
921
2 minutes
20
The introduction of automated insulin delivery (AID) systems has enabled increasing numbers of individuals with type 1 diabetes (T1D) to improve their glycemic control largely. However, use of AID systems is limited due to their complexity and costs associated. The user must wear both a continuously monitoring glucose system and an insulin infusion pump. The glucose sensor and the insulin catheter must be inserted at two different body sites using different insertion devices. In addition, the user must pair and manage the different systems. These communicate with the AID software implemented on the pump or on a third device such as a dedicated display device or smart phone application. These components might be developed and commercialized by different manufacturers, which in turn can cause difficulties for patients seeking technical support. A possible solution to these challenges would be to integrate the glucose sensor and insulin catheter into a single device. This would allow the glucose sensor and insulin catheter to be inserted simultaneously, eliminating the need for pairing, and simplifying system management. In recent years, different technologies have been developed and evaluated in clinical investigations that combine the glucose sensor and the insulin catheter in one platform. The consistent finding of all these studies is that integration has no adverse effect on insulin infusion and glucose measurements provided that certain conditions are met. In this review, we discuss the perceived challenges of such an approach and discuss possible solutions that have been proposed.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11874455 | PMC |
http://dx.doi.org/10.1177/19322968231203237 | DOI Listing |
Diabet Med
September 2025
Edinburgh Centre for Endocrinology & Diabetes, NHS Lothian, Edinburgh, UK.
Aims: This study aimed to assess the impact of the Omnipod 5 automated insulin delivery (AID) system on continuous glucose monitoring (CGM) metrics, HbA1c, and weight in a real-world setting. Additionally, independent predictors of glycaemic response were assessed.
Methods: Observational analysis of adults with type 1 diabetes using Omnipod 5 (n = 353).
NMR Biomed
October 2025
High-Field MR Center, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.
The human kidneys play a pivotal role in regulating blood pressure, water, and salt homeostasis, but assessment of renal function typically requires invasive methods. Deuterium metabolic imaging (DMI) is a novel, noninvasive technique for mapping tissue-specific uptake and metabolism of deuterium-labeled tracers. This study evaluates the feasibility of renal DMI at 7-Tesla (7T) to track deuterium-labeled tracers with high spatial and temporal resolution, aiming to establish a foundation for potential clinical applications in the noninvasive investigation of renal physiology and pathophysiology.
View Article and Find Full Text PDFG Ital Nefrol
August 2025
UO Nefrologia e Dialisi, Ospedale di Cassino, Italia.
SGLT-2 inhibitors are a relatively new class of antidiabetic drugs. They activate a transcriptional response similar to calorie restriction characterized by the up-regulation of sensors involved in nutrient deprivation, such as SIRT1 and AMPK, and the down-regulation of mTOR, a molecule involved in nutritional excess signaling. The purpose of this review is to illustrate the main pathways of nutrient deprivation: a complex mechanistic framework partly responsible for the cardio-renal benefits that makes these drugs unique.
View Article and Find Full Text PDFNat Rev Endocrinol
September 2025
Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital (USZ) and University of Zurich (UZH), Zurich, Switzerland.
Wearable technologies that analyse non-conventional biological matrices, such as interstitial fluid, sweat, tears or breath, have the potential to provide longitudinal biomarker data with minimal invasiveness. These data could provide insights into physiological and behavioural patterns, in particular outside medical care facilities. Despite the success of continuous glucose monitoring, the adoption of wearable sensors for managing endocrine and metabolic diseases remains limited.
View Article and Find Full Text PDFProg Mol Biol Transl Sci
September 2025
School of Forensic Science, National Forensic Sciences University, Gandhinagar, Gujarat, India.
Ingestible biosensors are a mix of advanced biomedical engineering, digital health and precision pharmacotherapy. These miniaturised electronic devices are encapsulated in biocompatible materials, which operate within gastrointestinal (GI) tract. This enables real-time monitoring of pharmacological and physiological parameters.
View Article and Find Full Text PDF